APL has begun collaborations with CurifyLabs to optimise the administration of medicines to children and critically ill patients.
The extemporaneous medicine CDMO plans to do this by using 3D printing technology, which can produce more personalised dosage forms.
It also allows for flexibility in the shape and structure of the dose, while enabling precise dosages to be delivered to frail or vulnerable patients, reducing the risk of serious side effects.
According to APL, its manufacturing method produces around 100 capsules per batch, though 3D printing allows the creation of precise doses, reducing the prevalence of waste in the manufacturing process.
Erik Haeffler, CEO at APL, commented: “3D printing is an exciting technology which shows significant promise in extemporaneous manufacturing."
CurifyLabs' CEO, Charlotta Topelius, added: “APL has demonstrated its strong capabilities in extemporaneous medicines with high quality and consistency, which will be critical to accelerating our development efforts together. We look forward to combining our strengths to create even greater value for patients needing personalized medicines,”
APL estimates that its 3D-printed extemporaneous medicines will be available to the Swedish market by 2025.